microRNAs delineate stable and reproducible markers for lung cancer and may play important role in non-invasive diagnostic marker. We have previously discovered miRNA signatures in the exhaled breath condensate (EBC) that are suitable for early diagnostics of various lung diseases. Since miRNAs have roles in the pathogenesis of lung diseases, they can be potentially useful in the early diagnosis of lung cancer and may as well complement the other conventional investigative methods such as low dose computerized tomography (LDCT) to avoid high false positive rates. Due to paucity of thoracic surgeons and interventional bronchoscopists in India, the inaccessibility of the suspected tumor tissue for pathological diagnosis is a big challenge. All India Institute of Medical Sciences, New Delhi is one of the pioneer institutions that provides medical care to patients coming from different ethnic and socioeconomic backgrounds in India. Based on our previous work and expertise in this area along with emerging consensus in the field, this work is expected to yield promising outcomes. Method: Exhaled Breath Condensate Collection: Samples were collected from the suspected NSCLC patients during OPD by using RTube. miRNA isolation from c-DNA synthesis using Quantimir qPCR kit qPCR reaction setup for profiling Bronchoscopy procedure: Bronchial brushings were collected after obtaining written informed consent during routine diagnosis. miRNA isolation c-DNA synthesis by using Kit from Applied Biosystems qPCR reaction setup by using Kapafast SybrGreen Result: In this study, we found the pro tumorigenic miRNAs like miR-19a, miR-33b, miR-558 are found to be upregulated and anti-tumor miRNAs like let7b, miR-132 and miR-181c found to be downregulated in the exhaled breath of NSCLC patients. Further we validated these miRNAs in bronchial brushings samples taken from respected patients. Surprisingly; those miRNAs showed positive trend. Conclusion: In this study, we have found various differentially expressed MicroRNAs in the exhaled breath as well as bronchial brushings samples taken from diagnosed NSCLC patients. The known pro tumorigenic miRNAs were found to be upregulated and anti tumorigenic miRNAs were downregulated. Hence, these biomarkers could either be used as a preliminary non-invasive screening method for the diagnosis of NSCLC. Apart from this, these identified miRNAs could be novel therapeutic targets for the treatment of NSCLC Background: Lung cancer screening provides an opportunity for early detection, improved survival and tobacco cessation. The purpose of this report is to provide outcome measures and lessons learned during the first five years at Stony Brook's Center for Lung Cancer Screening and Prevention. Method: The screening programs' REDCap database was queried for the results. Demographic information, CAT scan data, lung cancer diagnoses, adherence rates, and tobacco cessation rates were computed. Result: TCLCSP has enrolled 825 patients. 26 patients (3.15%) were diagnosed with lung cancer. Lessons Learned: Program Growth and Maintenance: Program growth has a direct relation to advertisement, community education and satisfactory reviews from PCPs. Low cost poster and brochure advertisements are effective. Database is key. Adherence: Successful adherence requires education, positive experience, distress management and a patient coordinator. Tobacco Cessation: Tobacco cessation counseling success is dose dependent and telephone counseling provides added opportunities. Tobacco reduction plans are a viable option. Conclusion: Lung cancer screening program success is achievable with ongoing outcome reviews and program revisions as needed. The lung cancer screening patient population will benefit from shared program information and ongoing research. 
